logo
logo

Remix Therapeutics Closes $70 Million Series B Financing

May 17, 2022•about 3 years ago

Amount Raised

$70 Million

Round Type

series b

Cambridge

Description

Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, today announced the close of a $70 million Series B financing. Surveyor (a Citadel company) joined the Series B syndicate alongside existing investors Foresite Capital, Atlas Venture, The Column Group, Arch Venture Partners, Alexandria Venture Investments, and Casdin Capital. The funds will support development of the company's REMaster technology platform and advancement of a pipeline of RNA processing targeted therapeutics.

Company Information

Company

Remix Therapeutics

Location

Cambridge, Maryland, United States

About

Remix Therapeutics is a biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. The REMaster technology platform makes it possible to identify patterns in RNA processing and exploit them to modulate gene expression. Remix's innovative therapeutic approach has the ability to alter the way genes are read from the genome, to correct, enhance, or eliminate the gene message, thereby addressing disease drivers at their origin. For more information visit www.remixtx.com. SOURCE Remix Therapeutics

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech